Canada markets close in 44 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
62.97+0.87 (+1.40%)
As of 3:16PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close62.10
Open62.35
Bid63.09 x 800
Ask63.08 x 1100
Day's Range62.11 - 63.42
52 Week Range60.89 - 85.97
Volume4,912,918
Avg. Volume8,677,293
Market Cap78.947B
Beta (5Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)-0.20
Earnings DateOct. 22, 2020 - Oct. 26, 2020
Forward Dividend & Yield2.72 (4.33%)
Ex-Dividend DateSep. 14, 2020
1y Target Est79.08
  • High-Voltage Analog Multiplexers from Diodes Incorporated Provide Signal Distribution in Industrial IoT Applications
    Business Wire

    High-Voltage Analog Multiplexers from Diodes Incorporated Provide Signal Distribution in Industrial IoT Applications

    Diodes Incorporated (Nasdaq: DIOD) today announced the introduction of the PS508 and PS509 analog multiplexers that are capable of switching signal voltages of up to 36V in an industrial environment. The high voltage capability of the devices will support industrial IoT (IIoT) applications using multiple sensors, including factory automation and process control, battery monitoring systems, and test and measurement equipment.

  • Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020
    Business Wire

    Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the HIV Glasgow 2020 conference, taking place virtually from October 5-8. Gilead will present 13 studies from the company’s HIV research and development programs in addition to supporting several other independent studies at the conference, which, along with its community-focused programs, reflect Gilead’s ongoing focus and commitment to advancing scientific discovery and supporting the development and delivery of practical solutions that can help improve care for all people affected by HIV.

  • Better Buy: Gilead Sciences vs. Amgen
    Motley Fool

    Better Buy: Gilead Sciences vs. Amgen

    These big biotechs are both moving into new areas. Which is most likely to move the needle for investors?